Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2002 | CellGate | Series D | 10M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2007 | ViaCyte | Series C | 0 |
| 7/2002 | Transvascular | Series D | 10.8M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 11/2013 | Biocartis | Series E | 0 |
| 1/2011 | Zeo | Series C | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 10/2007 | Tengion | Series C | 33M |
| 6/2006 | Tengion | Series B | 50M |
| 10/2007 | Syntaxin | Series B | 32M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 1/2015 | Willow | Series A | 15M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 7/2011 | Nevro | Series B | 58M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 8/2005 | Tengion | Series A | 39M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 3/2013 | Nevro | Series C | 0 |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2004 | Accumetrics | Series B | 0 |
| 4/2014 | Binx Health | Series B | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 93M |
| 11/2004 | Corthera | Series B | 15M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 11/2014 | La Lumiere | Series B | 20M |
| 7/2003 | Immunicon | Series F | 24.8M |
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 1/2014 | PowerVision | Series D | 0 |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 11/2011 | Biocartis | Series C | 95.8M |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 2/2008 | InSound Medical | Series E | 11M |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2007 | Optherion | Series A | 37M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2009 | ImaCor | Series A | 0 |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 2/2016 | Cala Health | Series B | 0 |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 4/2002 | Replidyne | Series A | 13M |
| 4/2010 | Biocartis | Series B | 40M |
| 9/2014 | Biocartis | Series F | 0 |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 1/2011 | 23andMe | Series C | 9M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 1/2012 | PowerVision | Series C | 12.5M |
| 6/2001 | NitroMed | Series E | 0 |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 7/2013 | CVRx | Series F | 0 |
| 9/2004 | Vascular Architects | Series E | 0 |
| 8/2005 | 7TM Pharma | Venture Round | - |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 11/2009 | Celladon | Series C | 21.8M |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 5/2007 | CVRx | Series D | 65M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 2/2012 | Celladon | Venture Round | 43M |
| 12/2012 | Biocartis | Series D | 0 |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 6/2009 | Pronota | Series B | 7.4M |
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 3/2011 | Astute Medical | Series B | 13M |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 4/2006 | Pronota | Series A | 7.8M |
| 9/2009 | NovoCure | Venture Round | - |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 10/2010 | Intio | Series B | 8.1M |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 9/2009 | Neotract | Series B | 28.1M |
| 5/2012 | Mitralign | Series D | 0 |
| 3/2017 | Grail | Series B | 0 |
| 1/2012 | Pronota | Series C | 4.8M |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 11/2003 | CardioMEMS | Series B | 0 |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 7/2005 | Ilypsa | Series B | 36M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2000 | Lumenos | Series B | 34M |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 12/2007 | Mitralign | Series C | 0 |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 11/2010 | Syntaxin | Series C | 29M |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 7/2008 | CVRx | Series E | 0 |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
